|
1
|
Sripa B and Pairojkul C:
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol.
24:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blechacz BR and Gores GJ:
Cholangiocarcinoma. Clin Liver Dis. 12:131–150. 2008. View Article : Google Scholar
|
|
3
|
Motari E, Zheng X, Su X, Liu Y,
Kvaratskhelia M, Freitas M and Wang PG: Analysis of recombinant
CD24 glycans by MALDI-TOF-MS reveals prevalence of sialyl-T
antigen. Am J Biomed Sci. 1:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aigner S, Sthoeger ZM, Fogel M, Weber E,
Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M and
Altevogt P: CD24, a mucin-type glycoprotein, is a ligand for
P-selectin on human tumor cells. Blood. 89:3385–3395.
1997.PubMed/NCBI
|
|
5
|
Wang H, Wang W, Wang X, Cai K, Wu H, Ju Q,
Huang Z and Gao X: Reduced N-Myc downstream-regulated gene 2
expression is associated with CD24 upregulation and poor prognosis
in patients with lung adenocarcinoma. Med Oncol. 29:3162–3168.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng J, Gao G, Wang L, Wang T, Yu J and
Zhao Z: CD24 expression as a marker for predicting clinical outcome
in human gliomas. J Biomed Biotechnol. 2012:5171722012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikenaga N, Ohuchida K, Mizumoto K, Yu J,
Kayashima T, Hayashi A, Nakata K and Tanaka M: Characterization of
CD24 expression in intraductal papillary mucinous neoplasms and
ductal carcinoma of the pancreas. Hum Pathol. 41:1466–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JH, Kim SH, Lee ES and Kim YS: CD24
overexpression in cancer development and progression: A
meta-analysis. Oncol Rep. 22:1149–1156. 2009.PubMed/NCBI
|
|
9
|
Lee HJ, Kim DI, Kwak C, Ku JH and Moon KC:
Expression of CD24 in clear cell renal cell carcinoma and its
prognostic significance. Urology. 72:603–607. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu J, Zhang G and Lu H: CD24, COX-2, and
p53 in epithelial ovarian cancer and its clinical significance.
Front Biosci (Elite Ed). 4:2745–2751. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Gong HL, Zhou L, Tian J and Wang Y:
CD24: a novel cancer biomarker in laryngeal squamous cell
carcinoma. ORL J Otorhinolaryngol Relat Spec. 74:78–85. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Keeratichamroen S, Leelawat K, Thongtawee
T, Narong S, Aegem U, Tujinda S, Praditphol N and Tohtong R:
Expression of CD24 in cholangiocarcinoma cells is associated with
disease progression and reduced patient survival. Int J Oncol.
39:873–881. 2011.PubMed/NCBI
|
|
13
|
Rattanasinganchan P, Leelawat K,
Treepongkaruna SA, Tocharoentanaphol C, Subwongcharoen S,
Suthiphongchai T and Tohtong R: Establishment and characterization
of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.
World J Gastroenterol. 12:6500–6506. 2006.PubMed/NCBI
|
|
14
|
Bajetto A, Barbero S, Bonavia R, Piccioli
P, Pirani P, Florio T and Schettini G: Stromal cell-derived
factor-1alpha induces astrocyte proliferation through the
activation of extracellular signal-regulated kinases 1/2 pathway. J
Neurochem. 77:1226–1236. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki Y, Rahman M and Mitsuya H: Diverse
transcriptional response of CD4(+) T cells to stromal cell-derived
factor (SDF)-1: cell survival promotion and priming effects of
SDF-1 on CD4(+) T cells. J Immunol. 167:3064–3073. 2001.
|
|
16
|
Leelawat K, Leelawat S, Narong S and
Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4
induced cholangiocarcinoma cell invasion. World J Gastroenterol.
13:1561–1568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sagiv E, Starr A, Rozovski U, Khosravi R,
Altevogt P, Wang T and Arber N: Targeting CD24 for treatment of
colorectal and pancreatic cancer by monoclonal antibodies or small
interfering RNA. Cancer Res. 68:2803–2812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bretz NP, Salnikov AV, Perne C, Keller S,
Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer
G and Altevogt P: CD24 controls Src/STAT3 activity in human tumors.
Cell Mol Life Sci. 69:3863–3879. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bretz N, Noske A, Keller S, Erbe-Hofmann
N, Schlange T, Salnikov A, Moldenhauer G, Kristiansen G and
Altevogt P: CD24 promotes tumor-cell invasion by suppressing tissue
factor pathway inhibitor-2 (TFPI-2) in a Src-dependent fashion.
Clin Exp Metast. 29:27–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ye P, Nadkarni MA, Simonian M and Hunter
N: CD24 regulated gene expression and distribution of tight
junction proteins is associated with altered barrier function in
oral epithelial monolayers. BMC Cell Biol. 10:22009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brand S, Dambacher J, Beigel F, Olszak T,
Diebold J, Otte JM, Göke B and Eichhorst ST: CXCR4 and CXCL12 are
inversely expressed in colorectal cancer cells and modulate cancer
cell migration, invasion and MMP-9 activation. Exp Cell Res.
310:117–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li JK, Yu L, Shen Y, Zhou LS, Wang YC and
Zhang JH: Inhibition of CXCR4 activity with AMD3100 decreases
invasion of human colorectal cancer cells in vitro. World J
Gastroenterol. 14:2308–2313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sutton A, Friand V, Brulé-Donneger S,
Chaigneau T, Ziol M, Sainte-Catherine O, Poiré A, Saffar L, Kraemer
M, Vassy J, Nahon P, Salzmann JL, Gattegno L and Charnaux N:
Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12
stimulates human hepatoma cell growth, migration, and invasion. Mol
Cancer Res. 5:21–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fischer GF, Majdic O, Gadd S and Knapp W:
Signal transduction in lymphocytic and myeloid cells via CD24, a
new member of phosphoinositol-anchored membrane molecules. J
Immunol. 144:638–641. 1990.PubMed/NCBI
|
|
25
|
Stefanová I, Horejsí V, Ansotegui IJ,
Knapp W and Stockinger H: GPI-anchored cell-surface molecules
complexed to protein tyrosine kinases. Science. 254:1016–1019.
1991.PubMed/NCBI
|
|
26
|
Zarn JA, Zimmermann SM, Pass MK, Waibel R
and Stahel RA: Association of CD24 with the kinase c-fgr in a small
cell lung cancer cell line and with the kinase lyn in an
erythroleukemia cell line. Biochem Biophys Res Commun. 225:384–391.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sammar M, Gulbins E, Hilbert K, Lang F and
Altevogt P: Mouse CD24 as a signaling molecule for
integrin-mediated cell binding: functional and physical association
with src-kinases. Biochem Biophys Res Commun. 234:330–334. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang W, Wang X, Peng L, Deng Q, Liang Y,
Qing H and Jiang B: CD24-dependent MAPK pathway activation is
required for colorectal cancer cell proliferation. Cancer Sci.
101:112–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J,
Wang X and Jiang B: Lyn is involved in CD24-induced ERK1/2
activation in colorectal cancer. Mol Cancer. 11:432012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhuang L, Lee CS, Scolyer RA, McCarthy SW,
Palmer AA, Zhang XD, Thompson JF, Bron LP and Hersey P: Activation
of the extracellular signal regulated kinase (ERK) pathway in human
melanoma. J Clin Pathol. 58:1163–1169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ge X, Fu YM and Meadows GG: U0126, a
mitogen-activated protein kinase kinase inhibitor, inhibits the
invasion of human A375 melanoma cells. Cancer Lett. 179:133–140.
2002. View Article : Google Scholar : PubMed/NCBI
|
